Curated pharmacogenomic, clinical, and drug-discovery datasets — each with structured provenance ready for FDA AI/ML submissions. Ready in minutes, not 6–12 months.
An internal PGx data team costs $300K–$500K/year in salaries alone — before infrastructure, license negotiation, and 6–12 months to first usable dataset. Attester delivers the same output on day one.
See pricing →Every record is sourced from CIViC, PharmGKB, DailyMed, or ClinicalTrials.gov, scored S0–S5 for evidence strength, and auto-approved for clinical evidence (S4/S5).
| gene | drug | disease | state | confidence | source |
|---|---|---|---|---|---|
| BRAF | Vemurafenib | Melanoma | S4 | 0.91 | CIViC |
| CYP2D6 | Codeine | Pain management | S5 | 0.96 | PharmGKB |
| EGFR | Erlotinib | Non-small cell lung | S4 | 0.88 | CIViC |
| DPYD | Fluorouracil | Colorectal cancer | S5 | 0.94 | PharmGKB |
| KRAS | Cetuximab | Colorectal cancer | S4 | 0.87 | DailyMed |
Every dataset ships with cleared commercial license terms. No 6-week legal review to discover your use case isn't permitted.
Every record carries an S0–S5 evidence state and a Markov-derived confidence score. Filter to S4/S5 for only validated clinical evidence.
Each dataset includes a structured FDA Provenance Data Card — source provenance, curation methodology, limitations, and governance chain. Drop it in your pre-submission package.
CIViC, PharmGKB, DailyMed, and ClinicalTrials.gov are ingested on a rolling schedule. New records appear automatically — no manual refresh.
Explorer plan is free — full catalog access, schema preview, and 5 sample records per dataset. Upgrade to Builder for full downloads, API access, and provenance PDFs.